June 25th 2025
In this CME article, learn more about the complexities of neuropsychiatric symptoms in Parkinson disease, including psychosis and cognitive impairment, and effective treatment strategies.
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
Southern Florida Psychiatry Conference
November 21-22, 2025
Register Now!
Real Psychiatry 2026
January 23-24, 2026
View More
Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
View More
Optimizing Care for Patients With Tardive Dyskinesia
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Hundreds of uniquely adapted venomous marine cone snail species inhabit the coral reefs of the Indian and Pacific oceans. Researchers posit that each may be a virtual neurologic pharmacopoeia with potential value for the treatment of everything from diabetic neuropathy to schizophrenia. The venoms, known as conotoxins, selectively inhibit a wide range of ion channels involved in neuromuscular signaling.
Read More
Better Tools Needed to Measure Treatment Outcome
October 1st 2006The need for better tools, as well as better use of existing tools, to measure treatment response in clinical trials was a principle focus of the 46th annual NIMH-sponsored NCDEU (New Clinical Drug Evaluation Unit) meeting, held June 12-15 in Boca Raton, Fla. Improved clinical research techniques are needed to better separate treatment effect from placebo response, to distinguish between active comparators, and to facilitate development of novel treatments, according to several presenters at the conference.
Read More
IOM Report Takes on Medication Errors . . . Again
October 1st 2006In its latest report on medication errors, a committee assembled by the Institute of Medicine (IOM) included some sidebars on psychiatric drugs. The report, issued in July, said that there is too little data on misadministration of psychiatric drugs and that clinical trials with psychiatric drugs have been small and incapable of providing pragmatic, comparative information.
Read More
Ampakines May Reverse Age-Related Memory Loss
September 1st 2006Ampakines, agents that have been shown to enhance memory, appear to trigger endogenous brain-derived neurotrophic factor (BDNF), a natural mechanism in the brain that could restore neuronal viability and synaptic plasticity through increased trophic support.
Read More
Preventing Rehospitalization in Schizophrenia
September 1st 2006Interventions addressing symptom education, service continuity, and daily structure are the most effective in avoiding inpatient stays in patients with schizophrenia who have had multiple hospitalizations, a study in the June issue of The Journal of Nervous and Mental Disease reported.
Read More
New Approaches to Juvenile Delinquency: Psychopathology, Development, and Neuroscience
September 1st 2006New findings in epidemiology, developmental psychiatry, and neuroscience offer the opportunity for a new perspective on the problems of juvenile delinquency and bring to bear the insights of modern psychiatry in the treatment and successful rehabilitation of juvenile offenders.
Read More
The Role of Family Therapy for Adolescents With Anorexia Nervosa
September 1st 2006The inclusion of parents in their children's treatment for eating disorder is not universally accepted. However, recent studies suggest that families should be included in treatment and that they are often a powerful resource for helping their children recover.
Read More
Borderline Personality Disorder: An Overview
August 25th 2006DSM-IV-TR emphasizes that patients with borderline personality disorder (BPD) show a "instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts," and any five out of nine listed criteria must be present for the diagnosis to be made.
Read More
Bipolar Disorder: Diagnostic Challenges and Treatment Strategies
August 1st 2006The past few years have seen substantial progress in recognizing and treating several of the subtypes of bipolar disorder. This Special Report addresses the diagnostic challenges and the different strategies for managing these subtypes.
Read More
Interventions to Improve Adherence to Antipsychotic Medications
August 1st 2006New ways to address medication adherence problems in patients with schizophrenia offer the hope of better treatment outcomes. Two new and promising approaches for individuals with schizophrenia are the use of environmental supports and cognitive adaptation training and cognitive-behavioral therapy.
Read More
Since its initial description by Kahlbaum (1828-1899) over a century ago, catatonia has been associated with psychiatric, neurologic, and medical disorders. Contemporary authors view catatonia as a syndrome of motor signs in association with disorders of mood, behavior, or thought. Some motor features are classic but infrequent (eg, echopraxia, waxy flexibility) while others are common in psychiatric patients (eg, agitation, withdrawal), becoming significant because of their duration and severity.
Read More